Review of Dopamine Antagonists for Nausea and Vomiting in Palliative Care Patients

References

• Miller K, Miller M. Managing common gastrointestinal symptoms at the end of life. J Hosp Palliat Nurs. 2002;4(1):34–42. doi:10.1097/00129191-200201000-00013.
   Google Scholar
• Miller A, Leslie R. The area postrema and vomiting. Front Neuroendocrinol. 1994;15(4):301–20. ISSN 0091-3022. doi:10.1006/frne.1994.1012.
   PubMed Web of Science ®Google Scholar
• Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59. doi:10.2147/CIA.S13109.
   PubMed Web of Science ®Google Scholar
• Zaporowska-Stachowiak I, Stachowiak-Szymczak K, Oduah M, Sopata M. Haloperidol in palliative care: indications and risks. Biomed Pharmacother. 2020;132:110772. ISSN 0753-3322. doi:10.1016/j.biopha.2020.110772.
   PubMed Web of Science ®Google Scholar
• Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: past and present. Indian J Psychiatry. 2009;51(4):324–26. doi:10.4103/0019-5545.58304.
   PubMedGoogle Scholar
• Masman AD, van Dijk M, Tibboel D, Baar FPM, Mathôt RAA. Medication use during end-of-life care in a palliative care centre. Int J Clin Pharm. 2015;37(5):767–75. doi:10.1007/s11096-015-0094-3.
   PubMed Web of Science ®Google Scholar
• Hardy J, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage. 2010;40(1):111–6. ISSN 0885-3924. doi:10.1016/j.jpainsymman.2009.11.321.
   PubMed Web of Science ®Google Scholar
• Davis M, Hui D, Davies A, Ripamonti C, Capela A, DeFeo G, Del Fabbro E, Bruera E. MASCC antiemetics in advanced cancer updated guideline. Support Care Cancer. 2021;29(12):8097–107. doi:10.1007/s00520-021-06437-w.
   PubMed Web of Science ®Google Scholar
• Madariaga A, Lau J, Ghoshal A, Dzierżanowski T, Larkin P, Sobocki J, Dickman A, Furness K, Fazelzad R, Crawford GB, et al. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. Support Care Cancer. 2022;30(6):4711–28. doi:10.1007/s00520-022-06889-8.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Palliative care (version 2.2023). https://www.nccn.org/professionals/physician_gls/pdf/ palliative.pdf.
   Google Scholar
• Someya T, Shibasaki M, Noguchi T, Takahashi S, Inaba T. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol. 1992; (3):169–74. PMID: 1629382.
   PubMed Web of Science ®Google Scholar
• Kudo S, Ishizaki T. Pharmacokinetics of haloperidol. Clin Pharmacokinet. 1999;37(6):435–56. doi:10.2165/00003088-199937060-00001.
   PubMed Web of Science ®Google Scholar
• Watson, Max, and others (eds). Oxford Handbook of Palliative Care. 3rd ed. Oxford Medical Handbooks (Oxford, 2019. online ed., Oxford Academic, 1 July 2019).
   Google Scholar
• Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care. 2013;30(1):75–82. doi:10.1177/1049909112441241.
   PubMed Web of Science ®Google Scholar
• Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655–63. Epub 2013 Jan 12. PMID: 23314603. doi:10.1007/s00520-012-1710-6.
   PubMed Web of Science ®Google Scholar
• Keisuke K, Masahiro K, Tatsuya M. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage. 2012;44(4):604–607. ISSN 0885-3924. doi:10.1016/j.jpainsymman.2011.10.023.
   PubMed Web of Science ®Google Scholar
• Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the treatment of advanced cancer–related chronic nausea and/or vomiting: a randomized pilot trial. JAMA Oncol. 2020;6(6):895–9. doi:10.1001/jamaoncol.2020.1052.
   PubMed Web of Science ®Google Scholar
• Thomas K, Saadabadi A. Olanzapine. [Updated 2022 Sep 8]. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK532903/
   Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Clin Pharmacokinet. 1999;37(3):177–93. doi:10.2165/00003088-199937030-00001.
   PubMed Web of Science ®Google Scholar
• Zyprexa (olanzapine). Package Insert. Eli Lilly and Company; 1997.
   Google Scholar
• Stahl S. 2017. Stahl’s essential psychopharmacology: prescriber’s guide. In Prescriber’s Guide: Stahl’s Essential Psychopharmacology. 6th ed. Cambridge: Cambridge University Press.
   Google Scholar
• Din L, Preuss CV. Prochlorperazine. [Updated 2022 Sep 21]. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK537083/
   Google Scholar
• Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med. 2011;14(7):810–4. doi:10.1089/jpm.2011.0058.
   PubMed Web of Science ®Google Scholar
• Baines M, Oliver D, Carter R. Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet. 1985;2(8462):990–3. ISSN 0140-6736. doi:10.1016/S0140-6736(85)90534-3.
   PubMed Web of Science ®Google Scholar
• Compazine (prochlorperazine). Package Insert. GlaxoSmithKline; 2004.
   Google Scholar
• Collins JM, Finn AL, Voyksner RD, et al. In-vitro characterization of the metabolism of prochlorperazine. Clin Pharmacol Ther. 2004;75:85.
   Web of Science ®Google Scholar
• Tashiro M, Naito T, Kagawa Y, Kawakami J. Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients. Ann Clin Biochem. 2018;55(3):385–93. Epub 2017 Oct 12. PMID: 28853295. doi:10.1177/0004563217731432.
   PubMed Web of Science ®Google Scholar
• Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991;32(6):677–84. PMID: 1768559; PMCID: PMC1368546.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol. 2018;9:913. PMID: 30233361; PMCID: PMC6131675. doi:10.3389/fphar.2018.00913.
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379–90. doi:10.1111/j.1365-2036.2004.01867.x.
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99–112. doi:10.1111/j.1365-2982.2007.01059.x.
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage. 2000;19(6):427–35. doi:10.1016/s0885-3924(00)00138-x.
   PubMed Web of Science ®Google Scholar
• Reglan (metoclopramide). Package Insert. ANI Pharmaceuticals Inc; Revised August 2017.
   Google Scholar
• Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet. 1983;8(6):523–29. PMID: 6360466. doi:10.2165/00003088-198308060-00003.
   PubMed Web of Science ®Google Scholar
• Ge S, Mendley SR, Gerhart JG, Melloni C, Hornik CP, Sullivan JE, Atz A, Delmore P, Tremoulet A, Harper B, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee, et al. Population pharmacokinetics of metoclopramide in infants, children, and adolescents. Clin Transl Sci. 2020;13(6):1189–98. Epub 2020 May 27. PMID: 32324313; PMCID: PMC7719387. doi:10.1111/cts.12803.
   PubMed Web of Science ®Google Scholar
• Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30(3):336–43. PMID: 11854155. doi:10.1124/dmd.30.3.336.
   PubMed Web of Science ®Google Scholar
• Al-Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited. Neurogastroenterol Motil. 2019;31(11):e13617. doi:10.1111/nmo.13617.
   PubMedGoogle Scholar